ArticleInfection and drug resistance2020
Molecular Epidemiology and Mechanisms of High-Level Resistance to Meropenem and Imipenem in
Article in Infection and drug resistance, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Worldwide threatening prevalence of carbapenem-resistantEpidemiology and infection · 2025Pooled it
- Prevalence of meropenem-resistant Pseudomonas Aeruginosa in Ethiopia: a systematic review and meta‑analysis.Antimicrobial resistance and infection control · 2024Pooled it
- Multidrug-resistant Pseudomonas aeruginosa in ICU patients and hospital surfaces: β-lactamase burden, biofilm formation and clonal spread.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Phylogenomic and phenotypic profiling of carbapenem-resistantMicrobial genomics · 2026Article
- Molecular Epidemiology of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Low levels of the second messenger c-di-GMP enhance tolerance and resistance to meropenem inFrontiers in cellular and infection microbiology · 2026Article
- Occurrence of Virulence and Antibiotic Resistance inAntibiotics (Basel, Switzerland) · 2025Article
- Article
- Resistance in gram-negative bacilli: the emergence of RND efflux pumps.Future microbiology · 2025Review
- Isolation and Molecular Characterization of Antimicrobial-Resistant Bacteria from Vegetable Foods.Pathogens (Basel, Switzerland) · 2025Article
- Antimicrobial and Anti-Efflux Machinery of FDA-Approved Proton Pump Inhibitors and Vitamins AgainstMicroorganisms · 2025Article
- Zinc sulfate acts as an efflux pump inhibitor on Pseudomonas aeruginosa clinical isolates.World journal of microbiology & biotechnology · 2025Article
- Regulation, structure, and activity of theAntimicrobial agents and chemotherapy · 2025Review
- Nanomedicine approaches to enhance the effectiveness of meropenem: a strategy to tackle antimicrobial resistance.Discover nano · 2025Review
- Reversal of carbapenem resistance in Pseudomonas aeruginosa by camelid single domain antibody fragment (VHH) against the C4-dicarboxylate transporter.The Journal of antibiotics · 2024Article
- Phenotypic and genotypic assessment of fluoroquinolones and aminoglycosides resistances in Pseudomonas aeruginosa collected from Minia hospitals, Egypt during COVID-19 pandemic.BMC infectious diseases · 2024Article
- Identification ofVeterinary world · 2024Article
- Article
- High incidence of carbapenemase-producingJAC-antimicrobial resistance · 2023Article
- Transcriptional profilingMicrobiology (Reading, England) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSTRAINS AND
methodsA total of 634 P. aeruginosa clinical isolates were collected from various patient sources and their MIC levels were measured. Molecular evaluation of carbapenem resistance was assessed by investigating the presence of
resultsCarbapenem resistance was detected in 32 (5%) isolates, which were all imipenem resistant (of which 29 were meropenem resistant). High-level resistance (≥64mg/mL) to imipenem was found in 27 (84.3%) isolates, and to meropenem in 28 (96.5%) isolates. The carbapenemase
conclusionHigh-level carbapenem resistance reported in this study was allied to multiple mechanisms including carbapenemase production and efflux-pump over-expression. Threatening cross-infection is possible inside the hospital and stringent infection control measures are crucial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.